Nausea typically appears between days 37 of your first injection, peaking around day 510 before improving by week 46
Customers report being unknowingly enrolled in a recurring billing subscription after their initial purchase
Retatrutide is an investigational triple agonist that targets three incretin and metabolic receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
Brand: RxSpan MD, operated by RxSpan MD LLC Headquarters: 465 N Roxbury Drive, Penthouse Suite, Beverly Hills, CA 90210 Founder (brand-stated): Dr
Neither is FDA-approved specifically for hair loss, and this is an off-label, compounded use of both
Aggressive dosing creates extreme caloric deficits